Skip to content
2000
Volume 13, Issue 9
  • ISSN: 1570-1808
  • E-ISSN: 1875-628X

Abstract

Benign prostatic hyperplasia is non-malignant enlargement of prostate gland which results in severe lower urinary tract symptoms and affects the quality of life of patients. 5α-Reductase inhibitors play a crucial role in the management of benign prostatic diseases with low toxicity and have been a major thrust area for its application in prostate cancers with limited success. In continuation of our program to develop novel 5α-reductase inhibitors, we report herein the synthesis and biological evaluation of 5a-oxo-5-aza-B-homo-3,5-seco-4-nor-cholestan-3-oic acid and 25(R)-5a-oxo-5-aza- B-homo-3,5-seco-4-nor-spirostan-3-oic acid derivatives. In vitro evaluation using human embryonic kidney cell line (HEK) based assay revealed compound MK-234 as most potent inhibitor with an IC50 value of 0.474 ±0.041 μM followed by MK-233 with an IC50 value 4.84 ± 0.088 μM as compared to clinically used drug finasteride (IC50 = 30.3 nM). Compound MK-235 and MK-236 also exhibited moderate inhibition with an IC50 value of 9.24 ± 0.796 and 13.148 ± 0.379 μM, respectively. Additionally, in silico ADME predictive studies were also carried out to assess the ‘druggability properties’ of the synthesised compounds.

Loading

Article metrics loading...

/content/journals/lddd/10.2174/1570180813666160630110649
2016-11-01
2025-07-04
Loading full text...

Full text loading...

/content/journals/lddd/10.2174/1570180813666160630110649
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test